الفهرس 
Evaluation of the prevalence and significance of hepatic steatosis in HIV/HCV co-infected Egyptian patients compared to those with HIV mono- infection
AbstractOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
Background: Human immune deficiency virus (HIV) and hepatitis C virus (HCV) are considered to be a global health problem. 36.7 million people are infected by HIV; 17 Million of them are on antiretroviral therapy. The prevalence of HIV in Egypt is 0.03 among the general population and ranges from 0.05 - 0.5 among people with high risk behavior. Due to similarities in mode of transmission; a large group of HIV/HCV has been discovered. An estimated 4–5 million people are infected with both HIV and HCV worldwide, they represent about 10-15% of HIV prevalence.
Aim of the study: This study aimed at evaluating the prevalence and significance of hepatic steatosis in HIV/HCV co-infected Egyptian patients compared to those with HIV mono-infection.
Patients and methods: This was a cross sectional study done in Kasr Al-Aini Viral Hepatitis Center (KAVHC), Faculty of Medicine, Cairo University, and included2 groups of patients; 50 adult patients with HIV/HCV co-infection (group A) and 50 adult patients with HIV mono-infection (group B). Patients were subjected to: CBC, serum creatinine, INR, total bilirubin, AST, ALT, GGT, Alkaline phosphatase, serum albumin, AFP, HBa1c for diabetic patients, HBsAg, HCV Ab, HCV PCR, HIV PCR and CD4 T-lymphocyte count. Abdominal ultrasound was done, and evaluation of liver stiffness and hepatic steatosis were done using fibroscan and controlled attenuated parameter (CAP).
Results: The median age was 35 years and 33 years in groups A and B respectively, and there was a statistically significant male predominance in the studied patients. BMI was significantly higher in group B compared to group A, and was a significant independent predictor of significant hepatic steatosis (CAP<238). Also abdominal wall thickness was significantly higher in patients with significant hepatic steatosis(CAP<238). Our studys howed no statistically significant differences as regard the CAP score and the different steatosis stages between both groups. However, liver stiffness was significantly higher in group A with HIV/HCV coinfection compared to group B with HIV mono-infection The prevalence of steatosis in group A was 36% versus 46.2% in group B.
.
Conclusion:The prevalence of steatosis was lower in HIV-HCV co-infected patients compared to HIV monoinfected group; we cannot say that HCV has a protective role against steatosis in co-infected patients. More fibrosis progression was common in the HIV- HCV co-infected patients